SAMHSA Bars Fentanyl Test Strips and Syringes From Federal Block Grant Spending

On April 24, 2026, SAMHSA issued a Dear Colleague letter withdrawing federal eligibility under block grant and discretionary grant programs for a core set of harm reduction tools: fentanyl test strips, sterile water, saline, ascorbic acid, sterile syringes, safer smoking supplies, and overdose hotlines.

The directive arrives as the broader federal addiction-response apparatus faces its deepest resource contraction in decades. At least $257 million in addiction and overdose prevention programs have been cut from SAMHSA’s budget, and the agency has seen staffing reductions of up to 50 percent.

What Is and Isn’t Covered

The April letter is precise about what remains eligible for federal funding: naloxone and nalmefene, medication lock boxes, sharps disposal, wound care, FDA-approved home testing kits for HIV and viral hepatitis, navigation to PrEP and PEP, and condom distribution.

This creates a notable split: federally funded programs can treat the wounds caused by injection drug use and provide naloxone after an overdose, but cannot fund the equipment that might prevent either injury — a syringe or a strip that detects fentanyl in a supply.

The Xylazine and Fentanyl Co-Contamination Context

The policy shift coincides with documented co-contamination of the methamphetamine and stimulant supply by fentanyl in multiple markets. For people who smoke rather than inject drugs, safer smoking supplies are the relevant harm reduction tool — and they are now excluded. Meanwhile, xylazine is not reversed by naloxone; without test strips, people cannot know whether xylazine is present before using.

Why This Matters for People in Recovery

Public health and harm reduction organizations have characterized the directive as a reversal of the evidence base on overdose prevention.

Find naloxone distribution sites and treatment resources in Arizona through Rize.